The Centers for Disease Control and Prevention (CDC) National Center for Emerging and Zoonotic Infectious Diseases for (NCEZID) in Atlanta, Georgia, intends to negotiate a sole source Blanket Purchase Agreement (BPA) with Illumina, Inc., under authority of Federal Acquisition Regulation (FAR) Subpart 6.302-1, Other Than Full and Open Competition procedures and FAR Part 13, Simplified Acquisition Procedures, for the acquisition of Illumina, Inc. next generation library preparation, instrumentation, product care plans, and sequencing reagents/consumables. The reagents and consumables being procured are in a pre-configured format and will fit directly into the cBOT, HiSeq, MiSeq and NextSeq Next Generation Sequencing Instruments. The continued use of Illumnia Inc. platform is required to assure continuity of research within the labs in which considerable amounts of data have already been accumulated using this sequencing platform. Ordering from another source would compromise experiments and compromise the integrity of data. These supplies and reagents are covered by various patents and use of other than Original Equipment Manufacturer (OEM) will void warranty and service agreement as well as invalidate test results. Illumina Sequencing Systems employ proprietary reagents and supplies specifically formulated for the Illumina sequencing system platforms located at CDC. This is a notice of intent and is not a request for competitive quotes or proposals. No solicitation is available. Firms that believe they can meet the requirement are encouraged to identify themselves and provide a substantive statement with descriptive literature and any other supporting information to the Contracting Officer within 15 days of publication of this notice. All information received within 15 days of publication of this synopsis will be considered by the Government to determine if more than one firm can meet the Government's requirements and is capable of providing technically acceptable equipment, chemical reagents and services. Responses to this posting must be submitted in writing via e-mail only. A determination not to compete the described requirement based upon responses to this notice is solely within the discretion of the Federal Government. Information received will be considered solely for the purpose of determining whether or not to conduct a competitive procurement. Any questions or comments should be directed via e-mail ONLY to Le Doan at
[email protected]. Thank you for your interest.